Clinical Interventions in Aging
Volume 15, 2020 - Issue
Open access
130
Views
8
CrossRef citations to date
0
Altmetric
Original Research
Teriparatide in East Asian Postmenopausal Women with Osteoporosis in a Real-World Setting: A Baseline Analysis of the Asia and Latin America Fracture Observational Study (ALAFOS)
Chung-Hwan Chen1 Department of Orthopedics and Orthopedic Research Center, Kaohsiung Municipal Ta-Tung Hospital and Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan
https://orcid.org/0000-0001-8941-4792
Seung-Jae Lim2 Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
https://orcid.org/0000-0002-7209-9690
Jong-Keon Oh3 Department of Orthopedics, Korea University Guro Hospital, Seoul, South Korea
, Tsan-Wen Huang4 Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan
, Yuhong H Zeng5 Department of Osteoporosis, Honghui Hospital, Xi ‘an Jiaotong University, Xian, People’s Republic of China
https://orcid.org/0000-0002-8805-0066
Meng-Ting Wu6 Division of Neurosurgery, Department of Surgery, Cheng Hsin General Hospital, Taipei, Taiwan
https://orcid.org/0000-0002-4655-6907
Huilin L Yang7 Department of Orthopedics, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China
https://orcid.org/0000-0002-0617-2597
Jason Pui-Yin Cheung8 Department of Orthopaedics and Traumatology, The University of Hong Kong, Hong Kong, People’s Republic of China
https://orcid.org/0000-0002-7052-0875
Ji Wan Kim9 Department of Orthopedic Surgery, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea
https://orcid.org/0000-0002-3524-8706
Jeong Hee Han10 Department of Medical Quality and Regulatory Affairs, Lilly Korea Ltd., Seoul, South Korea
, Li Huo11 Lilly China Drug Development and Medical Affairs Center, Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, People’s Republic of China
https://orcid.org/0000-0002-2476-4182
Tsung-Jung Lin12 Department of Medical Affairs, Eli Lilly and Company (Taiwan), Inc., Taipei, Taiwan
, Gang Zhou11 Lilly China Drug Development and Medical Affairs Center, Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, People’s Republic of China
& Wen-Shuo Wu12 Department of Medical Affairs, Eli Lilly and Company (Taiwan), Inc., Taipei, TaiwanCorrespondence[email protected]
https://orcid.org/0000-0002-6259-3409
Pages 111-121
|
Published online: 30 Jan 2020
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.